{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T10:41:22Z","timestamp":1775904082966,"version":"3.50.1"},"reference-count":27,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T00:00:00Z","timestamp":1380499200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:sec id=\"S109285291300059X_abs1\" sec-type=\"general\"><jats:title>Objective\/Introduction<\/jats:title><jats:p>Lurasidone is an atypical antipsychotic medication approved for the treatment of schizophrenia over a dose range of 40\u2013160 mg\/day. This study examined D<jats:sub>2<\/jats:sub>receptor occupancy and its association with clinical improvement and side effects in patients with schizophrenia or schizoaffective disorder following repeated doses of 80, 120, or 160 mg\/day of lurasidone.<\/jats:p><\/jats:sec><jats:sec id=\"S109285291300059X_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Twenty-five patients with<jats:italic>The Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>, 4th ed. (DSM-IV) diagnoses of schizophrenia or schizoaffective disorder were washed out of their antipsychotic medications (5 half-lives) and randomly assigned to 80, 120, or 160 mg\/day of lurasidone. Subjects were imaged with 18F-fallypride at baseline and at steady-state lurasidone treatment to determine D<jats:sub>2<\/jats:sub>receptor occupancy.<\/jats:p><\/jats:sec><jats:sec id=\"S109285291300059X_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Blood lurasidone concentration (plus major metabolite), but not dose, significantly correlated with D<jats:sub>2<\/jats:sub>receptor occupancy. D<jats:sub>2<\/jats:sub>receptor occupancy in several subcortical structures is associated with positive but not negative symptom improvement or the presence of movement symptoms.<\/jats:p><\/jats:sec><jats:sec id=\"S109285291300059X_abs4\" sec-type=\"discussion\"><jats:title>Discussion<\/jats:title><jats:p>Blood concentrations greater than 70 ng\/mL may be required to achieve a 65% occupancy level in subcortical areas. Intersubject blood concentrations at fixed dose were highly variable and may account for the lack of dose correlations.<\/jats:p><\/jats:sec><jats:sec id=\"S109285291300059X_abs5\" sec-type=\"conclusion\"><jats:title>Conclusions<\/jats:title><jats:p>Positron emission tomography (PET) occupancy data suggest that greater than 65% occupancy can be achieved across the dose range of 80\u2013160 mg\/day and that some patients require higher doses to achieve antipsychotic efficacy; this finding supports prior randomized clinical trial results.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s109285291300059x","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T10:30:06Z","timestamp":1380537006000},"page":"176-181","source":"Crossref","is-referenced-by-count":31,"title":["D<sub>2<\/sub>receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder"],"prefix":"10.1017","volume":"19","author":[{"given":"Steven G.","family":"Potkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Keator","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn L.","family":"Kesler-West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo. G. M.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jogeshwar","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikunj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Preda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2013,9,30]]},"reference":[{"key":"S109285291300059X_ref3","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903286388"},{"key":"S109285291300059X_ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300931"},{"key":"S109285291300059X_ref22","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800250087012"},{"key":"S109285291300059X_ref18","doi-asserted-by":"publisher","DOI":"10.1109\/NSSMIC.2011.6153705"},{"key":"S109285291300059X_ref9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10060907"},{"key":"S109285291300059X_ref21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"S109285291300059X_ref6","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10128"},{"key":"S109285291300059X_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(99)00012-8"},{"key":"S109285291300059X_ref2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04905"},{"key":"S109285291300059X_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.01.009"},{"key":"S109285291300059X_ref16","doi-asserted-by":"publisher","DOI":"10.1109\/NSSMIC.2005.1596770"},{"key":"S109285291300059X_ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02587.x"},{"key":"S109285291300059X_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S109285291300059X_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.02.013"},{"key":"S109285291300059X_ref5","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.712114"},{"key":"S109285291300059X_ref4","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"S109285291300059X_ref19","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-199609000-00008"},{"key":"S109285291300059X_ref25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07101574"},{"key":"S109285291300059X_ref14","doi-asserted-by":"crossref","unstructured":"Guy W . Clinical Global Impression Scale: The ECDEU Assessment Manual for Psychopharmacology\u2014Revised. Volume DHEW, Publ. No. ADM 76, 1976; Vol. 338: 218\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"S109285291300059X_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2006.11.003"},{"key":"S109285291300059X_ref11","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1625"},{"key":"S109285291300059X_ref23","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.5.818"},{"key":"S109285291300059X_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(93)90288-O"},{"key":"S109285291300059X_ref20","article-title":"Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects","author":"Wong","journal-title":"Psychopharmacology (Berl)"},{"key":"S109285291300059X_ref13","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S109285291300059X_ref26","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283498ecf"},{"key":"S109285291300059X_ref17","doi-asserted-by":"publisher","DOI":"10.1109\/NSSMIC.2006.353723"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S109285291300059X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T02:14:06Z","timestamp":1564193646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S109285291300059X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,30]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S109285291300059X"],"URL":"https:\/\/doi.org\/10.1017\/s109285291300059x","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,30]]}}}